Drugs / zamzetoclax
last change Jun 2025 re-read 2 minutes ago

zamzetoclax

Small molecule

Developed for
cancer
Investigated by
Gilead Sciences

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05006794 Sep 2021 → Jun 2025 cancer Gilead Sciences Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as zamzetoclax ClinicalTrials.gov intervention name — accepted as the source's own label NCT05006794
Modality Small molecule CHEMBL6068037
Route Oral “Tablet(s) administered orally” NCT05006794